UPDATE: bluebird bio Q2 EPS $(0.67) Beats $(0.72) Estimate, Sales $6.89M Miss $9.31M Estimate
Portfolio Pulse from Benzinga Newsdesk
bluebird bio (NASDAQ:BLUE) reported Q2 earnings per share of $(0.67), beating the analyst consensus estimate of $(0.72) by 6.94%. However, the company's quarterly sales of $6.89 million missed the analyst consensus estimate of $9.31 million by 25.99%. Despite the sales miss, this represents a 353.59% increase over sales from the same period last year.
August 08, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
bluebird bio's Q2 earnings beat estimates but sales missed. This mixed result could lead to uncertain short-term price movements.
bluebird bio's Q2 earnings beat analyst estimates, which is a positive signal. However, the company's sales missed estimates, which is a negative signal. These mixed signals could lead to uncertain short-term price movements for the company's stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100